Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

Serum levels of osteopontin as a prognostic factor in patients with oral squamous cell carcinoma

verfasst von: Maryam Mardani, Azadeh Andisheh-Tadbir, Bijan Khademi, Mohammad Javad Fattahi, Shapour Shafiee, Maryam Asad-Zadeh

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Osteopontin (OPN) is a multifunctional glycophosphoprotein that was detected in many carcinomas, and it may have a prognostic role. The aim of this study was to determine osteopontin serum levels in patients with oral squamous cell carcinoma (OSCC) and investigated its correlation with clinicopathological features of tumor. Using an ELISA kit, we assessed and compared the circulating levels of OPN in blood serum of 45 oral squamous cell carcinoma patients with 45 healthy control samples. The serum osteopontin level in patients with OSCC was significantly higher (145.8 ± 14.6 ng/ml, n = 45) compared with the healthy controls (53.9 ± 9.6 ng/ml, n = 45, p < 0.001). Mean serum osteopontin level was significantly higher in patients with nodal metastasis (p = 0.03) and higher stage (p = 0.02). Findings of the present study suggest that OPN may have a potential role in pathogenesis of OSCC and it may be used as a tool for monitoring tumor progression.
Literatur
1.
Zurück zum Zitat Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 1979;16:885–93.PubMedCrossRef Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 1979;16:885–93.PubMedCrossRef
2.
Zurück zum Zitat Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993;7:1475–82.PubMed Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993;7:1475–82.PubMed
3.
4.
Zurück zum Zitat Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta (BBA)-Rev Cancer. 2001;1552:61–85.CrossRef Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta (BBA)-Rev Cancer. 2001;1552:61–85.CrossRef
5.
Zurück zum Zitat Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2007;57:373–80.CrossRef Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2007;57:373–80.CrossRef
6.
Zurück zum Zitat Wong TS, Kwong DL, Sham J, Wei WI, Kwong YL, Yuen AP. Elevation of plasma osteopontin level in patients with undifferentiated nasopharyngeal carcinoma. Eur J Surg Oncol Eur Soc Surg Oncol Br Assoc Surg Oncol. 2005;31:555–8. Wong TS, Kwong DL, Sham J, Wei WI, Kwong YL, Yuen AP. Elevation of plasma osteopontin level in patients with undifferentiated nasopharyngeal carcinoma. Eur J Surg Oncol Eur Soc Surg Oncol Br Assoc Surg Oncol. 2005;31:555–8.
7.
Zurück zum Zitat Chiu YW, Tu HF, Wang IK, Wu CH, Chang KW, Liu TY, et al. The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis. Oral Oncol. 2010;46:302–6.PubMedCrossRef Chiu YW, Tu HF, Wang IK, Wu CH, Chang KW, Liu TY, et al. The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis. Oral Oncol. 2010;46:302–6.PubMedCrossRef
8.
Zurück zum Zitat Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A Japanese lung cancer registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008;3:46–52.PubMedCrossRef Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A Japanese lung cancer registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008;3:46–52.PubMedCrossRef
9.
Zurück zum Zitat Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol. 1995;146:95.PubMedCentralPubMed Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol. 1995;146:95.PubMedCentralPubMed
10.
Zurück zum Zitat Takenaka M, Hanagiri T, Shinohara S, Yasuda M, Chikaishi Y, Oka S, et al. Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer. Clin Lung Cancer. 2013;14:288–94.PubMedCrossRef Takenaka M, Hanagiri T, Shinohara S, Yasuda M, Chikaishi Y, Oka S, et al. Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer. Clin Lung Cancer. 2013;14:288–94.PubMedCrossRef
11.
Zurück zum Zitat Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 2004;10:184–90.PubMedCrossRef Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 2004;10:184–90.PubMedCrossRef
12.
Zurück zum Zitat Eto M, Kodama S, Nomi N, Uemura N, Suzuki M. Clinical significance of elevated osteopontin levels in head and neck cancer patients. Auris Nasus Larynx. 2007;34:343–6.PubMedCrossRef Eto M, Kodama S, Nomi N, Uemura N, Suzuki M. Clinical significance of elevated osteopontin levels in head and neck cancer patients. Auris Nasus Larynx. 2007;34:343–6.PubMedCrossRef
13.
Zurück zum Zitat Matsuzaki H, Shima K, Muramatsu T, Ro Y, Hashimoto S, Shibahara T, et al. Osteopontin as biomarker in early invasion by squamous cell carcinoma in tongue. J Pathol Med. 2007;36:30–4.CrossRef Matsuzaki H, Shima K, Muramatsu T, Ro Y, Hashimoto S, Shibahara T, et al. Osteopontin as biomarker in early invasion by squamous cell carcinoma in tongue. J Pathol Med. 2007;36:30–4.CrossRef
14.
Zurück zum Zitat Routray S, Kheur SM, Kheur M. Osteopontin: a marker for invasive oral squamous cell carcinoma but not for potentially malignant epithelial dysplasias. Ann Diagn Pathol. 2013;17:421–4.PubMedCrossRef Routray S, Kheur SM, Kheur M. Osteopontin: a marker for invasive oral squamous cell carcinoma but not for potentially malignant epithelial dysplasias. Ann Diagn Pathol. 2013;17:421–4.PubMedCrossRef
15.
Zurück zum Zitat Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomark Prev. 2004;13:487–91. Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomark Prev. 2004;13:487–91.
16.
Zurück zum Zitat Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, et al. Co-expression of osteopontin and cd44v9 in gastric cancer. Int J Cancer. 1998;79:127–32.PubMedCrossRef Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, et al. Co-expression of osteopontin and cd44v9 in gastric cancer. Int J Cancer. 1998;79:127–32.PubMedCrossRef
17.
Zurück zum Zitat Saitoh Y, Kuratsu J-I, Takeshima H, Yamamoto S, Ushio Y. Expression of osteopontin in human glioma: its correlation with the malignancy. Lab Investig. 1995;72:55–63.PubMed Saitoh Y, Kuratsu J-I, Takeshima H, Yamamoto S, Ushio Y. Expression of osteopontin in human glioma: its correlation with the malignancy. Lab Investig. 1995;72:55–63.PubMed
18.
Zurück zum Zitat Le Q-T, Sutphin PD, Raychaudhuri S, Yu SCT, Terris DJ, Lin HS, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res. 2003;9:59–67.PubMed Le Q-T, Sutphin PD, Raychaudhuri S, Yu SCT, Terris DJ, Lin HS, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res. 2003;9:59–67.PubMed
19.
Zurück zum Zitat Hirama M, Takahashi F, Takahashi K, Akutagawa S, Shimizu K, Soma S, et al. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett. 2003;198:107–17.PubMedCrossRef Hirama M, Takahashi F, Takahashi K, Akutagawa S, Shimizu K, Soma S, et al. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett. 2003;198:107–17.PubMedCrossRef
20.
Zurück zum Zitat Liu H, Chen A, Guo F, Yuan L. A short-hairpin RNA targeting osteopontin downregulates mmp-2 and mmp-9 expressions in prostate cancer pc-3 cells. Cancer Lett. 2010;295:27–37.PubMedCrossRef Liu H, Chen A, Guo F, Yuan L. A short-hairpin RNA targeting osteopontin downregulates mmp-2 and mmp-9 expressions in prostate cancer pc-3 cells. Cancer Lett. 2010;295:27–37.PubMedCrossRef
Metadaten
Titel
Serum levels of osteopontin as a prognostic factor in patients with oral squamous cell carcinoma
verfasst von
Maryam Mardani
Azadeh Andisheh-Tadbir
Bijan Khademi
Mohammad Javad Fattahi
Shapour Shafiee
Maryam Asad-Zadeh
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1506-4

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.